BlueCross BlueShield of Arizona
An Independent Licensee of the Blue Cross and Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 9/20/18
LAST REVIEW DATE: 8/15/19
LAST CRITERIA REVISION DATE: 8/15/19
ARCHIVE DATE:

TIBSOVO® (ivosidenib) oral tablet

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the request form in its entirety with the chart notes as documentation. **All requested data must be provided.** Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**

TIBSOVO® (ivosidenib) oral tablet

Criteria:

- **Criteria for initial therapy:** Tibsovo (ivosidenib) is considered ***medically necessary*** and will be approved when **ALL** of the following criteria are met:

  1. Prescriber is a physician specializing in cancer or is in consultation with an Oncologist

  2. Individual is 18 years of age or older

  3. A confirmed diagnosis of **ONE** of the following:
     - Relapsed or refractory acute myeloid leukemia (AML), as a component of repeating the initial successful induction regimen if late relapse (≥ 12 months) as a single agent
     - Newly-diagnosed AML in an adult patient who is ≥ 75 years old or who has comorbidities that preclude use of intensive induction chemotherapy (See Definitions section)
     - Other request for a specific oncologic direct treatment use that is found and listed in the National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1 and 2A

  4. **ALL** of the following baseline tests have been completed before initiation of treatment with continued monitoring as clinically appropriate:
     - A susceptible IDH1 mutation in the blood or bone marrow as detected by an FDA-approved test
     - Complete blood count with differential
     - Comprehensive metabolic panel
     - Electrocardiogram (ECG)

  5. Will not be used in patients also taking strong CYP3A4 inducers

  6. Will not be used in patients also taking itraconazole or ketoconazole

  7. Will not be used in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m^2) or renal impairment requiring dialysis

  8. Will not be used in patients with moderate to severe hepatic impairment (total bilirubin ≥ 1.5x the ULN and any value for AST)

  Initial approval duration: 6 months

- **Criteria for continuation of coverage (renewal request):** Tibsovo (ivosidenib) is considered ***medically necessary*** and will be approved when **ALL** of the following criteria are met:

  1. Individual continues to be seen by a physician specializing in cancer or is in consultation with an Oncologist

TIBSOVO® (ivosidenib) oral tablet

2. Individual's condition responded while on therapy
    - Response is defined as:
        - No evidence of disease progression

3. Individual has been adherent with the medication

4. Individual has not developed any significant level 4 adverse drug effects that may exclude continued use
    - Significant adverse effect such as:
        - QTc interval prolongation with signs and symptoms of life-threatening arrhythmia
        - Development of Guillain-Barre syndrome
        - Any severe or life-threatening toxicity that has recurred

5. Will not be used in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m^2) or renal impairment requiring dialysis

6. Will not be used in patients with moderate to severe hepatic impairment (total bilirubin ≥ 1.5x the ULN and any value for AST)

7. There are no significant interacting drugs

Renewal duration: 12 months

Description:

Tibsovo (ivosidenib) is an isocitrate dehydrogenase-1 (IDH1) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. Susceptible IDH1 mutations are defined as those leading to increased levels of 2-hydroxyglutarate (2-HG) in the leukemia cells and where efficacy is predicted by 1) clinically meaningful remissions with the recommended dose of ivosidenib and/or 2) inhibition of mutant IDH1 enzymatic activity at concentrations of ivosidenib sustainable at the recommended dosage according to validated methods. The most common of such mutations are R132H and R132C substitutions. Inhibition of the mutant IDH1 enzyme by ivosidenib leads to decreased 2-HG levels, reduced blast counts, and increased percentages of mature myeloid cells.

Definitions:

Co-morbidities that precluded the use of intensive induction chemotherapy based on at least **ONE** of the following criteria:

- Baseline Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 2
- Severe cardiac disease
- Severe pulmonary disease

- Hepatic impairment with bilirubin > 1.5 times the upper limit of normal
- Creatinine clearance < 45 mL/min

ECOG Performance status:

Eastern Co-operative Oncology Group (ECOG) Performance Status	
Grade	ECOG description
0	Fully active, able to carry on all pre-disease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
2	Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours
3	Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
4	Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
5	Dead
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982	

NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 2.2018, Aug 1, 2018

- Ivosidenib:
  - Used as a single agent in patients age ≥ 60 years with IDH1 mutated AML for:
    - Treatment induction when not a candidate for intensive remission induction therapy or declines intensive therapy
    - Post-remission therapy following response to previous lower intensity therapy
  - For relapsed/refractory disease in patients with IDH1 mutated AML
    - As a component of repeating the initial successful induction regimen if late relapse (≥ 12 months)
    - As a single agent

Acute Myeloid Leukemia:

Therapy for AML with FLT3-ITD mutation
Hypomethylating agents (5-azacytidine or decitabine) + sorafenib
Therapy for AML with IDH2 mutation
Enasidenib
Therapy for AML with IDH1 mutation
Ivosidenib
Therapy for CD33-positive AML
Gemtuzumab ozogamicin

TIBSOVO® (ivosidenib) oral tablet

Response criteria for AML:
CR (complete remission) was defined as <5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets >100,000/microliter and absolute neutrophil counts [ANC] >1,000/microliter).

CRh (complete remission with partial hematological recovery) was defined as <5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets >50,000/microliter and ANC >500/microliter).

DOR (duration of response) was defined as time since first response of CR or CRh to relapse or death, whichever is earlier.

Resources:

Tibsovo. Package Insert. Revised by manufacturer 7/20/18. Accessed 8/23/18.

Tibsovo (ivosidenib) product information accessed 07-17-19 at DailyMed

Off Label Use of Cancer Medications: A.R.S. §§ 20-826(R) & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions.

NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 2.2018, Aug 1, 2018.